All Stories

  1. First in vivo evaluation of the radiolabelled Hsp90 inhibitor [11C]onalespib for cancer and brain PET imaging
  2. 3p-C-NETA: A Versatile Theranostic Chelator Platform Enabling Al18F- and 177Lu-Labeled SSTR2-Targeted Radioligands
  3. First in vivo evaluation of the radiolabelled Hsp90 inhibitor [11C]Onalespib for cancer and brain PET imaging
  4. Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [18F]AlF-NOTA-SC, [177Lu]Lu-BL02, and [161Tb]Tb-BL02 for Theranostic Development
  5. Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients
  6. Affinity- and Format-Dependent Pharmacokinetics of 89Zr-Labeled Albumin-Binding VHH Constructs
  7. RBIO-09. Preclinical evaluation of the synergistic effect of heat shock protein 90 inhibitors with temozolomide and external beam radiotherapy in glioblastoma models
  8. [11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics
  9. In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy
  10. Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain
  11. Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia
  12. PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease
  13. Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CT
  14. In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration
  15. Radiosynthesis and Evaluation of [18F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging
  16. Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography
  17. Development and evaluation of Hsp90-targeting nanobodies for visualisation of extracellular Hsp90 in tumours using PET imaging
  18. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein
  19. Development and evaluation of deuterated [18F]JHU94620 isotopologues for the non-invasive assessment of the cannabinoid type 2 receptor in brain
  20. Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924
  21. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein
  22. Development and Evaluation of Deuterated [18F]JHU94620 Isotopologues for the Non-invasive Assessment of the Cannabinoid Type 2 Receptor in Brain
  23. HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics
  24. Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl...
  25. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a mult...
  26. Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging
  27. Highlight selection of radiochemistry and radiopharmacy developments by editorial board
  28. Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [18F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET
  29. Preclinical Evaluation of Novel PET Probes for Dementia
  30. Radiopharmaceuticals for Cancer Imaging and Therapy
  31. Author Correction: Reverse engineering synthetic antiviral amyloids
  32. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
  33. Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
  34. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging
  35. 18F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
  36. In Vivo Detection of Neurofibrillary Tangles by 18 F-MK-6240 PET/MR in Patients With Ischemic Stroke
  37. Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid α/β-Hydrolase Domain 6 (ABHD6)
  38. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging
  39. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
  40. 18F-AlF-NOTA-Octreotide Outperforms68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
  41. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin
  42. Structure-Based Design, Optimization, and Development of [18F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET
  43. Correction to: Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
  44. The PET tracer [ 11 C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer’s disease
  45. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals
  46. Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
  47. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
  48. Preclinical Evaluation of [11C]YC-72-AB85 for In Vivo Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography
  49. Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets
  50. Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
  51. Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain
  52. Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
  53. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
  54. Highlight selection of radiochemistry and radiopharmacy developments by editorial board
  55. On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion
  56. Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model
  57. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)
  58. Photo isomerization of cis‐cyclooctene to trans‐cyclooctene: Integration of a micro‐flow reactor and separation by specific adsorption
  59. Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain
  60. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
  61. Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects
  62. Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution
  63. Reverse engineering synthetic antiviral amyloids
  64. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
  65. Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour
  66. Photoisomerization of cis- to trans-cyclooctene: integration of a micro-flow reactor & separation by specific adsorption
  67. Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging
  68. Translation of HDAC6 PET Imaging Using [18F]EKZ-001–cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates
  69. Development and Evaluation of Interleukin-2–Derived Radiotracers for PET Imaging of T Cells in Mice
  70. Correction to Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer
  71. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper
  72. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation
  73. Automated GMP compliant production of [18F]AlF-NOTA-octreotide
  74. Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI
  75. Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
  76. Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging
  77. The Changing Landscape of Early Medicines Development: Be Prepared
  78. Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced α-synucleinopathy
  79. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study
  80. Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients
  81. Design and Challenges of Radiopharmaceuticals
  82. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient
  83. Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinson’s Disease
  84. Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma
  85. In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration
  86. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers
  87. Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles
  88. Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer
  89. Preclinical evaluation of [18 F]MA3: a CB2 receptor agonist radiotracer for PET
  90. Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain
  91. 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446
  92. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method
  93. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia
  94. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers
  95. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI‐microangiography‐histopathology in rats
  96. Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants
  97. Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
  98. Effects of alcohol exposure on the glutamatergic system: a combined longitudinal 18 F-FPEB and 1 H-MRS study in rats
  99. Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers
  100. Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats
  101. Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence
  102. Pretargeted PET Imaging Using a Bioorthogonal 18F-Labeled trans-Cyclooctene in an Ovarian Carcinoma Model
  103. Position statement on radiopharmaceutical production for clinical trials
  104. Cerebral dopaminergic and glutamatergic transmission relate to different subjective responses of acute alcohol intake: an in vivo multimodal imaging study
  105. Synthesis and preclinical evaluation of [ 11 C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)
  106. Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P
  107. Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration
  108. Synthesis, Enzyme Assays and Molecular Docking Studies of Fluorina ted Bioisosteres of Santacruzamate A as Potential HDAC Tracers
  109. Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease
  110. cGMP production of the radiopharmaceutical [18F]MK-6240 for PET imaging of human neurofibrillary tangles
  111. Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging
  112. Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging
  113. Cholinergic depletion and basal forebrain volume in primary progressive aphasia
  114. Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels–Alder reactions. Potential applications for pretargeted in vivo PET imaging
  115. Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)
  116. Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO2: Opportunities for 11C Radiochemistry
  117. The effect of isoflurane on 18F-FDG uptake in the rat brain: a fully conscious dynamic PET study using motion compensation
  118. De novo design of a biologically active amyloid
  119. [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP
  120. Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3
  121. Guidelines to PET measurements of the target occupancy in the brain for drug development
  122. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease
  123. What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2
  124. Positive Association Between Limbic Metabotropic Glutamate Receptor 5 Availability and Novelty-Seeking Temperament in Humans: An 18F-FPEB PET Study
  125. Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates
  126. Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
  127. Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission
  128. New Chelators for Low Temperature Al18F-Labeling of Biomolecules
  129. Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer18F-FPEB in human brain
  130. Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807
  131. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide
  132. The effect of anaesthesia on18F-FDG uptake in the rat brain: A fully conscious dynamic study using motion correction
  133. Preclinical Evaluation and Quantification of 18F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5
  134. Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET
  135. Retention of [18F]fluoride on reversed phase HPLC columns
  136. PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments
  137. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice
  138. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors
  139. Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [18F]MK-9470 PET Study
  140. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice
  141. Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans
  142. Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A
  143. EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
  144. PET Radioligands for In Vivo Visualization of Neuroinflammation
  145. Changes in Cerebral CB1Receptor Availability after Acute and Chronic Alcohol Abuse and Monitored Abstinence
  146. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease
  147. Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5)
  148. PET imaging shows loss of striatal PDE10A in patients with Huntington disease
  149. Development and biological evaluation of 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers
  150. Brain Imaging of Cannabinoid Receptors
  151. 11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists
  152. Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A
  153. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
  154. Lack of endogenous opioid release during sustained visceral pain: A [11C]carfentanil PET study
  155. Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa
  156. In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
  157. 18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study
  158. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis
  159. Quantification of 18F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test–Retest Study in Human Brain
  160. Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin αvβ3 expression in vivo
  161. Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [18F]FDG and [18F]FECT Functional Mapping of the Mouse Brain
  162. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study
  163. Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis
  164. Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects
  165. Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type‐1 receptors
  166. Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human
  167. New Transient Receptor Potential Vanilloid Subfamily Member 1 Positron Emission Tomography Radioligands: Synthesis, Radiolabeling, and Preclinical Evaluation
  168. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy
  169. 18F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity
  170. Preclinical evaluation of carbon-11 and fluorine-18 sulfonamide derivatives for in vivo radiolabeling of erythrocytes
  171. Synthesis and biological evaluation of [11C]SB366791: A new PET-radioligand for in vivo imaging of the TRPV1 receptor
  172. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging
  173. Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET
  174. Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging
  175. Optimized In Vivo Detection of Dopamine Release Using 18F-Fallypride PET
  176. Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model
  177. Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?
  178. Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging
  179. Preclinical evaluation and quantification of [18F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain
  180. Noninvasive Molecular Imaging of Neuroinflammation
  181. Recent Advances in Positron Emission Tomography (PET) Radiotracers for Imaging Phosphodiesterases
  182. Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy
  183. Measuring extrastriatal dopamine release during a reward learning task